Japanese Circulation Journal Vol.65, July 2001 tients and outpatients at Showa University Hospital and allied hospitals in Tokyo, Japan. All study subjects were Japanese.
First, 150 non-treated essential hypertension outpatients were randomly selected. Hypertension was diagnosed according to the following criteria: (a) systolic blood pressure was ≥140 mmHg or diastolic blood presssure was ≥90 mmHg without anti-hypertensive treatment, and the patient had a history of hypertension for more than 1 year; (b) the patient did not have clinical or biological signs of secondary hypertension; and (c) the patient did not have coronary heart disease, hyperlipidemia, diabetes mellitus, etc requiring treatment. The average blood pressure in these hypertensive subjects was 148/94 (168-140/102-90), therefore the hypertensive subjects in this group had mild hypertension.
Second, 150 healthy normotensive subjects on routine visits to a medical examination center (Tokyo, Japan) were recruited as controls. They were age-and sex-matched to the hypertensive subjects and accepted into the study if the systolic blood presssure and diastolic blood presssure were <140 and <90 mmHg, respectively, and there was not a familial history of hypertension. Their clinical status was confirmed by physical and laboratory examinations, including electrocardiography, and no history of cardiovascular diseases. All of their clinical data were within normal limits, including blood pressure, total cholesterol, and plasma glucose.
The blood pressure values of the hypertensive and normotensive subjects were the means of 2 measurements recorded 5 min apart in the patient in the sitting position after 15 min of rest. Blood samples were obtained after a fast of at least 12 h.
Third, 150 patients who underwent coronary angiography at Showa University Hospital, Tokyo, Japan in 1997-1999 were included. AMI was diagnosed by clinical evidence of cardiac attack, ECG criteria, and serum cardiac enzyme concentrations. The AMI patients were divided into 2 subgroups: AMI with/without hypertension. The presence of conventional risk factors such as hypertension, hypercholesterolemia, diabetes mellitus and smoking was determined from the medical records prior to admission because of AMI.
All subjects gave informed consent to participate in the study, and the study was approved by the Showa University Ethics Committee. Blood samples were collected from the peripheral vein and then genomic DNA was prepared from the white blood cells.
Determination of Genotypes
AngII Type 1 Receptor 1166 Adenine/Cytosine Polymorphism The detection of the AngII type 1 receptor 1166 A/C polymorphism was determined by polymerase chain reaction (PCR) and restriction isotyping using the restriction endonuclease Dde 1 and primers previously described by Doria et al. 10 Alleles were visualized on 2% agarose gels stained with ethidium bromide. PCR amplified a fragment encompassing the A/C polymorphic site at the 1166 nucleotide position in the 3' untranslated region of the human AngII type 1 receptor gene. The design of the primers was as follows: sense, 5'-ATAATGTAAGCTCATCCACC-3'; antisense, 5'-GAGATTGCATTTCTGTCAGT-3'. The 30-l reaction volume contained 100 ng genomic DNA, 10 pmol of each primer, 250 mol/L dNTP, 1.0 mmol/L MgCl2, 50 mmol/L KCl, 10 mmol/L Tris-HCl at pH 8.3, and 0.5 units of Taq polymerase. Amplification was carried out using a Thermal Cycler (Perkin Elmer 2400; CA, USA). The cycle conditions for PCR were heating for 5 min at 94°C, 40 cycles of 30 s at 94°C, 45 s at 55°C, and 45 s at 72°C as the main reaction, followed by a final extension at 72°C for 10 min. After confirming that the PCR products showed exact amplification, they were digested with Dde I for 3 h at 37°C. The digested products were visualized on 2% agarose gel by ethidium bromide staining.
AngII Type 2 Receptor 3123 Cytosine/Adenine Polymorphism We designed the following primers: sense, 5'-GGATTCAGATTTCTCTTTGAA-3'; antisense, 5'-GCAT-AGGAGTATGATTTAATC-3'. PCR was performed under the same conditions used for the AngII type 1 receptor gene polymorphism, with the exception of the annealing temperature, which was set at 53°C. After confirming DNA amplification, 10 l of the PCR product was digested with 12 units of Alu I for 3 h at 37°C, then electrophoresed on 2% agarose gel with ethidium bromide staining. 11, 12 BK-B2 Receptor -58 Thymine/Cytosine Polymorphism The primers for PCR amplification were sense, 5'-GCA-GAGCTCAGCTGGAGGAG-3', located in the promoter, and antisense 5'-CCTCCTCGGAGCCCAGAAG-3', located in the promoter/exon 1. Primers were designed from the BK-B2 receptor gene reported by Kammerer et al. 13 The total reaction volume was 100 l, in a mixture containing 1 g of genomic DNA, 50 ng of each primer, 200 mol of each dNTP, 1.5 mmol/L of MgCl2, and 0.5 units of Taq DNA polymerase. The cycle conditions for PCR were an initial step of 5 min at 94°C, followed by 30 cycles of 1 min at 94°C, 30 s at 58°C, and 30 s at 72°C, followed by a final extension of 5 min at 72°C. PCR products were subjected to single-strand conformation polymorphism (SSCP) electrophoresis. A 10-l aliquot of the PCR product was diluted with 30 l formamide, denatured at 95°C for 10 min, and subjected to SSCP analysis in a 20% polyacrylamide (2× TBE) gel. Electrophoresis was carried out in 2×TBE buffer at 24°C at 180 V for 20 h, and the gels were then silverstained. SSCP analysis of 450 unrelated Japanese subjects was performed in the same way. Several samples representative of each genotype detected by SSCP were sequenced by fluorescent cycle sequencing to confirm the thymine (T) or cytosine (C) at nucleotide position -58 upstream of the putative transcription start site. In samples obtained from 450 unrelated Japanese individuals, the 2 polymorphic alleles were disclosed by PCR-SSCP electrophoresis in a 20% polyacrylamide gel.
BK-B2 Receptor Exon 1 (+) [21] [22] [23] [24] [25] [26] [27] [28] [29] /(-) [21] [22] [23] [24] [25] [26] [27] [28] [29] Polymorphism A tandem repeat polymorphism was detected in exon 1 starting at nucleotide position 12 backward from the transcription site. 13 Thus, exon 1 exists in 2 different lengths, 102 or 93 base pairs; that is, (+) [21] [22] [23] [24] [25] [26] [27] [28] [29] or (-) [21] [22] [23] [24] [25] [26] [27] [28] [29] , respectively. Primers were designed from the BK-B2 receptor gene reported by Kammerer et al. 13 The forward and reverse primers were used for PCR amplifications: 5'-GCCCTTG-AAAGATGAGCTG-3', and 5'-AACTCCCCACGACCA-CAG-3' for exon 1. The total reaction volume was 50 l and included 1 g genomic DNA, 50 ng of each primer, 1.25 U Taq DNA polymerase, 200 mol of each dNTP, and 1.5 mmol/L MgCl2. The cycle conditions for PCR were an initial 5 min at 94°C, followed by 1 min at 94°C, 1 min at 53°C, and 1 min at 72°C for 40 cycles and a final extension time of 5 min at 72°C. PCR products were then electrophoresed on 2% agarose gel with ethidium bromide staining.
Statistical Analysis
Differences in clinical characteristics between the subjects were examined by ANOVA for parametric data. Differences in the genotype and allelic frequencies between the groups were analyzed using the chi-squared test, and Fisher's test was used for sets with small numbers. A probability of less than p<0.05 was taken to be significant.
Results
The clinical characteristics of the hypertensive, control and AMI subjects are shown in Table 1 . Blood examination data in the hypertensive and control subjects was not significantly different, and no clinical parameters requiring treatment were seen in either subject group. The presence of complicating conventional risk factors, such as hypercholesterolemia, diabetes mellitus and smoking, between AMI subjects with/without hypertension was not significantly different.
In the samples obtained from 450 unrelated Japanese individuals, PCR-restriction fragment length polymorphism (PCR-RFLP) electrophoresis in a 2% agarose gel disclosed 2 sets of 3 genotypes for the AngII type 1 and type 2 receptor gene polymorphisms, and PCR-SSCP electrophoresis in a 20% polyacrylamide gel disclosed 1 set of 3 genotypes for the BK-B2 receptor gene polymorphism. Fig 1 shows tion start site for the BK-B2 receptor gene polymorphism. The genotypes and allelic frequencies were in HardyWeinberg equilibrium. Table 2 shows the distributions of the genotypes and the allelic frequencies of the gene polymorphisms of AngII type 1 and type 2 receptors, and the BK-B2 receptor in hypertensive and control subjects. In the distributions of the genotype and the allelic frequency of the AngII type 1 receptor gene, there was no significant difference between the hypertensive and control subjects. However, the AngII type 2 receptor gene has been mapped to the X-chromosome, so here we only show the allelic frequency. A significantly higher incidence of the A allele was seen in hypertensive subjects compared with controls, and the odds ratio (OR) was estimated as 2.45 (95% confidence interval 1.70-3.54, p=0.001). Table 2 also shows the distributions of the genotype and allelic frequency of the BK-B2 receptor gene -58T/C polymorphism, and significantly higher incidences of the CC genotype (p=0.008) and C allele (OR 1.56 (95% CI 1.13-2.15, p=0.007)) were seen in hypertensive subjects compared with controls. However, in the distributions of the genotype and the allelic frequency of the BK-B2 receptor gene exon 1 (+) [21] [22] [23] [24] [25] [26] [27] [28] [29] /(-) [21] [22] [23] [24] [25] [26] [27] [28] [29] polymorphism, there was no polymorphism within the subjects. Furthermore, in the distributions of the genotypes and the allelic frequencies of these polymorphisms with regard to gender, there were no significant differences among the groups (data not shown). Thus, these results indicate that the AngII type 2 receptor A allele and the BK-B2 receptor C allele are associated with essential hypertension.
Next, we further examined these polymorphisms in AMI subjects with/without hypertension to determine whether they were associated with acceleration of atherosclerosis and the occurrence of AMI. Table 3 shows the distributions of the allelic frequencies of the gene polymorphisms of the AngII type 2 and BK-B2 receptors and it can be seen that there was no significant difference of the AngII type 2 receptor A allele between AMI subjects with/without hypertension. In contrast, a significantly higher incidence of the C allele of the BK-B2 receptor was seen in AMI subjects with hypertension compared with those without hypertension, and the OR was estimated as 1.66 (95% CI 1.05-2.62, p=0.031), which was significant, particularly in the younger AMI patients. In AMI subjects with hypertension aged less than 60 years old, a significantly higher incidence of the C allele of the BK-B2 receptor was detected, estimated as 2.02 (95% CI 1.05-3.86, p=0.033). Therefore, BK-B2 receptor -58T/C polymorphism was associated with not only with essential hypertension, but also with acceleration of atherosclerosis and the occurrence of AMI.
Furthermore, the distributions of the allelic frequencies of the gene polymorphisms of the AngII type 2 receptor and BK-B2 receptor in normotensive and hypertensive subjects with/without AMI showed that the AngII type 2 receptor A allele was associated with the occurrence of AMI in normotensive subjects (Table 4) , so this polymorphism might be related to other coronary risk factors. The BK-B2 receptor C allele was not associated with the occurrence of AMI in either normotensive or hypertensive subjects, so it is either not associated directly with the occurrence of AMI or hypertension may strongly influence the C allele. 
Discussion
From the genetic basis of essential hypertension and coronary heart disease, the ECTIM study showed that the ACE DD genotype was more frequent in patients with MI than in control subjects. 14, 15 Tiret et al also showed that the association between the ACE DD genotype and MI was increased in a subset of patients who also carried the AngII type 1 C allele, 15 and other studies have confirmed the association of the ACE D allele and the AngII type 1 receptor A/C genotype with an increased risk of essential hypertension and MI. [16] [17] [18] [19] The cellular effects of AngII are mediated by 2 structurally distinct receptor subtypes, the AngII type 1 and type 2 receptors, and most of known biological functions are mediated by the type 1 receptor, which is widely distributed in adult tissues. 20, 21 The expression of the AngII type 2 receptor is abundant in fetal tissues and scanty in adult tissues, [22] [23] [24] [25] and the mechanism of the type 2 receptor is still obscure. This receptor is re-expressed in MI, cardiac hypertrophy and vascular injury, 26, 27 which suggests that it is activated in various pathophysiological states and works cardioprotectively against the type 1 receptor. 28, 29 In addition, AngII receptor antagonists are now used clinically for hypertension and congestive heart failure. Their pharmacological mechanism is inhibition of the AngII type 1 receptor and stimulation of the type 2 receptor, 28, 30 but few studies have investigated the association between AngII type 2 receptor polymorphism and diseases.
Our results suggest that AngII type 1 receptor polymorphism is not associated with essential hypertension, but the AngII type 2 receptor A allele was associated with its occurrence. This polymorphism was not associated with AMI with/without hypertension, therefore it is unclear whether the AngII type 2 receptor A allele was associated with the acceleration of atherosclerosis by hypertension and the occurrence of AMI. However, this polymorphism was associated with the occurrence of AMI in normotensive subjects, so it might be related to other coronary risk factors.
It was reported that the AngII type 1 receptor 1166 A/C polymorphism might be a marker in linkage disequilibrium with an unidentified functional variant that could affect the regulation of the gene in response to AngII. 31, 32 In addition to the AngII type 1 receptor polymorphism, it was suggested that the AngII type 2 receptor polymorphism in itself does not cause cardiovascular disorders directly, but that this polymorphism may contribute to the development and progression of cardiovascular disease, started by other factors, such as the activity of plasma renin and its uptake by certain tissues that leads to local activation of the RAS. Therefore, this genetic variation becomes very important when combined with other factors.
Bradykinin in the kallikrein -kinin system is a vasoactive nonpeptide of the kinin family released from kininogenes via the proteolytic activity of kallikreins. 33, 34 It plays an important role in the cardiovascular system, affecting blood pressure regulation, cell proliferation and matrix synthesis by fibroblasts, 35, 36 and also acts cardioprotectively on the myocardium. 34, 37 Bradykinin acts mainly as a local hormone by activating specific receptors, known as the B1 and B2 receptors, the latter mediating most of the inflammatory and cardiovascular effects. 38, 39 The human B2 receptor gene is implicated as a candidate in the complex genetic underpinnings of essential hypertension and cardiovascular diseases. 40 Subsequent studies of the genomic structure have shown that it is characterized by 3 polymorphisms located in each of the 3 exons and 1 polymorphism located in the promoter region. 9,13, 41 Braun et al reported that the polymorphism of the promoter region may influence the transcription rate of the gene. They initiated in vitro transfection experiments in human embryonic kidney cells, and performed luciferase reporter gene assays to examine the effect of the 2 different alleles of the promoter on the transcription rate. There were differences in the extent of luciferase expression: the luciferase promoter assay of -58T was found to be higher than that of -58C. 9 Kammerer et al also reported that the promoter and exon 1 regions are related to transcription rate. 13 We previously reported that the low transcriptional activity of the BK-B2 receptor promoter polymorphism may cause the development of essential hypertension, 8 and in our present study, the BK-B2 receptor C allele was associated with not only with the occurrence of essential hypertension, but also with the acceleration of atherosclerosis by hypertension and the occurrence of AMI. However, this polymorphism was not associated directly with the occurrence of AMI. The low transcriptional activity of the BK-B2 receptor promoter may influence the transcription rate of the gene, and the occurrence of diseases, but in the Japanese population the BK-B2 receptor exon 1 (+) [21] [22] [23] [24] [25] [26] [27] [28] [29] /(-) 21-29 polymorphism does not have an effect on the occurrence of essential hypertension and AMI.
We analyzed the polymorphisms of the AngII type 1 and type 2 receptors and the BK-B2 receptor, and found significant differences of genotypes and allelic frequencies in the AngII type 2 receptor C/A and the BK-B2 receptor -58T/C polymorphisms between subjects with essential hypertension and control subjects. These polymorphisms are probably associated with an increased responsiveness to AngII and we conjecture that they promote the occurrence of essential hypertension. Further, the BK-B2 receptor -58T/C polymorphism was also associated with the acceleration of atherosclerosis and the occurrence of AMI. These genetic variations contribute to individual heterogeneity in the status of the RAS and kallikreins -kinin system, and thereby modify the role of these systems in essential hypertension and AMI.
In conclusion, genetic variations in the renin -angiotensin and kallikrein -kinin systems could prove to be significant pathophysiological mechanisms affecting essential hypertension and AMI, and genetic differences appear to be a new coronary risk factor for these diseases. This new marker provides a valuable tool to assess a patient's risk and the occurrence of these diseases may be able to be reduced by genetic management.
